| 英文别名 |
norfloxacin;1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylica;1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid;Norfloxacine;1-ethyl-6-fluoro-4-oxo-7-piperazinyl-1,4-dihydro-quinoline-3-carboxylic acid;1-ethyl-6-fluoro-7-piperazino-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid;4803P;am-715;Barazan;Fulgram;GMP;Noflo;noroxin;Utinor;WAKO149-08241;Zomxin;Zoroxin;1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid;Baccidal;Chibroxin;Floxacin 400;Norphloxacine;N-Desmethylpefloxacin;Sebercim;Norfloxacinum;Norfloxacino;Lexinor;NFLX;Norfloxacine [INN-French];1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid;Norfloxacinum [INN-Latin];Norfloxacino [INN-Spanish];AM 715;MK 0366;1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxy;MK-0366;Norfloxacin for system suitability;Norfloxacin for peak identification;7-(1-Piperazinyl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;KBio3_001607;Spectrum3_000524;BRN 0567897;NCGC00021725-03;Norfloxacin (USAN:USP:INN:BAN:JAN);GTPL12408;NCGC00016916-01;NCGC00016916-03;1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;DTXSID7037680;J01MA06;CS-1906;NORFLOXACIN (MART.);NORFLOXACIN (EP MONOGRAPH);NORFLOXACIN [JAN];CCG-40235;BRD-K11196887-001-22-0;C06687;1-ethyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid;BRD-K11196887-001-05-5;BIDD:GT0725;NORFLOXACIN [ORANGE BOOK];Norfloxacin (Norxacin);NORFLOXACIN [USP-RS];KBio2_001497;BDBM50045000;NCGC00016916-06;Norfloxacin, Antibiotic for Culture Media Use Only;KBioGR_000866;PEFLOXACINE_met009;Oprea1_375152;HMS2235G03;Spectrum4_000453;Norfloxacin, British Pharmacopoeia (BP) Reference Standard;EN300-06467;Epitope ID:119068;Noroxin (TN);Norfloxacin, European Pharmacopoeia (EP) Reference Standard;HMS2091J16;AKOS000417391;Tox21_110682_1;NORFLOXACIN [EP MONOGRAPH];BSPBio_002107;1-Ethyl-3-carboxy-6-fluoro-7-(piperazinyl-1)-quinolin-4(1H)-one;1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylicAcid;1-ethyl-6-fluoro-7-(1-piperazinyl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid;Norfloxacinum (INN-Latin);HMS1568N03;Norfloxacin, United States Pharmacopeia (USP) Reference Standard;EINECS 274-614-4;NORFLOXACIN (USP IMPURITY);SPBio_002182;1-ethyl-1,4-dihydro-6-fluoro-4-oxo-7-(1-piperazinyl)quinoline-3-carboxylic acid;NORFLOXACIN [INN];Norocin;NSC-757250;KBio2_006633;NCGC00016916-04;Chibroxine;HMS3712N03;HSDB 8029;NCGC00016916-12;1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid (Norfloxacin);Chibroxol;NORFLOXACIN (USP-RS);3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-;HY-B0132;UNII-N0F8P22L1P;NS00000224;AB00052059-19;Norfloxacino (INN-Spanish);Norfloxacin [USAN:USP:INN:BAN:JAN];Noracin;SPBio_001173;Tox21_11... |
